Consistently, topotecan treatment decreased SIRT1 expression, phosphorylation of Akt at Ser473 and mTOR at Ser2448, as well as EMT activity, but had minimal effects in USP22‐deficient melanoma cells (Figure S6D). The gene discussed is AKT1; the disease is melanoma.